ERBB2 and breast cancer: Despite the unique characteristics of BC histological types and the importance of HER-2 as a biomarker, the clinicopathologic model incorporating these factors demonstrated limited predictive power, yielding AUCs of 0.737 and 0.485 in the validation and test sets, respectively.